Dermatology Times

OCTOBER 11, 2023

The data presents compelling evidence for the sustained efficacy and safety of the oral JAK1 inhibitor in the treatment of moderate to severe atopic dermatitis over an extended 140-week period.

Dermatitis 81

Dermatitis Sustainability Safety Treatments 81

Dermatology Times

MARCH 14, 2025

Karl Yen of Sanofi discussed the role of amlitelimab in AD following sustained results and a promising safety profile presented in data at AAD.

Dermatitis 41

Dermatitis Sustainability Safety 41

The Dermatology Digest

JULY 27, 2023

Patricia Farris discusses skincare industry trends, including consumer demand for “clean beauty,” sustainability, and resources for consumer and dermatologist ingredient education. So we just don’t have the standardization of what is being eliminated and no consensus as to what should be eliminated based on safety studies.

Sustainability 36

Sustainability Skincare Safety Ingredients 36

The Dermatology Digest

OCTOBER 24, 2024

APG777 continues to show promise in atopic dermatitis (AD), according to early data. near-complete inhibition of pSTAT6 and sustained TARC inhibition out to nine months following a single dose These data will be presented at the American College of Allergy, Asthma & Immunology’s (ACAAI) 2024 Annual Scientific Meeting in Boston, MA.

Sustainability 36

Sustainability Dermatitis Safety Clinic 36

The Dermatology Digest

JANUARY 23, 2024

Nemolizumab improves skin lesions, itch, and sleep disturbance in patients with moderate-to-severe atopic dermatitis (AD), according to results from two phase 3 studies. Galderma’s nemolizumab is a first-in-class interleukin-31 receptor alpha antagonist that is under investigation for atopic dermatitis.

Dermatitis 36

Dermatitis Safety Eczema Sustainability 36

The Dermatology Digest

MARCH 11, 2024

Sanofi’s investigational OX40-ligand blocker amlitelimab produces sustained improvement in the signs and symptoms of atopic dermatitis (AD) in adults who previously responded and continued treatment and sustained off-drug improvements in those who stopped treatment.

Sustainability 36

Sustainability Dermatitis Safety Hospital 36

The Dermatology Digest

MARCH 5, 2024

Pharmacokinetic (PK) data showed a half-life of approximately 75 days across doses tested and pharmacodynamic (PD) data showed, deep and sustained inhibition of key atopic dermatitis (AD) biomarkers pSTAT6 and TARC for ~3 months (longest follow-up available, with inhibition still ongoing at time of the data cut).

Injections 36

Injections Safety Sustainability Clinic 36